School of Basic Medicine, College of Medicine, Qingdao University, Qingdao, China (mainland).
Jiaozhou Maternal and Child Health Hospital, Jiaozhou Maternal and Child Health Hospital, Qingdao, China (mainland).
Med Sci Monit. 2021 Jul 15;27:e931102. doi: 10.12659/MSM.931102.
BACKGROUND Epithelial splicing regulatory proteins (ESRPs), including ESRP1 and ESRP2, are important proteins for alternative splicing of mRNAs and are reported to promote or inhibit the progression of some tumors. However, the effects of ESRPs in breast cancer are still unknown. MATERIAL AND METHODS In this study, we detected the transcriptional level and alterations of ESRP1 in patients with breast cancer based on the Oncomine, Gene Expression Profiling Interactive Analysis, Gene Expression-Based Outcome for Breast Cancer Online, and cBioPortal databases. Using immunohistochemistry and quantitative polymerase chain reaction, the expression pattern of ESRP1 in breast cancer was analyzed. Analysis of the clinicopathological characteristics and function of ESRP1 in breast cancer were actualized through the University of Alabama Cancer database and Database for Annotation, Visualization and Integrated Discovery. Using the Kaplan-Meier plotter, the prognostic values of ESRP1 in patients with breast cancer were analyzed. The Encyclopedia of RNA Interactomes database was used to predict miRNAs that regulated ESRP1. RESULTS We found that ESRP1 was significantly overexpressed in patients with breast cancer, compared with patients without breast cancer, and had statistically significant clinicopathological characteristics. Kaplan-Meier plotter analysis indicated that the elevated expression of ESRP1 was associated with poor prognosis in patients with breast cancer. Furthermore, hsa-miR-181c-5p was identified to be potentially involved in the regulation of ESRP1. CONCLUSIONS These results suggest that ESRP1 is a valuable target for the precise treatment of breast cancer and a potential biomarker for the prognosis of patients with breast cancer.
上皮剪接调节蛋白(ESRPs),包括 ESRP1 和 ESRP2,是 mRNA 可变剪接的重要蛋白,据报道可促进或抑制某些肿瘤的进展。然而,ESRPs 在乳腺癌中的作用尚不清楚。
在这项研究中,我们基于 Oncomine、基因表达谱交互分析、乳腺癌在线基因表达预后和 cBioPortal 数据库检测了乳腺癌患者中 ESRP1 的转录水平和改变。通过免疫组织化学和定量聚合酶链反应分析了 ESRP1 在乳腺癌中的表达模式。通过阿拉巴马大学癌症数据库和注释、可视化和综合发现数据库对 ESRP1 在乳腺癌中的临床病理特征和功能进行了分析。通过 Kaplan-Meier 绘图器分析了 ESRP1 在乳腺癌患者中的预后价值。通过 RNA 相互作用组百科全书数据库预测了调节 ESRP1 的 miRNAs。
我们发现与没有乳腺癌的患者相比,ESRP1 在乳腺癌患者中显著过表达,并且具有统计学显著的临床病理特征。Kaplan-Meier 绘图器分析表明,ESRP1 的高表达与乳腺癌患者的预后不良相关。此外,hsa-miR-181c-5p 被鉴定为可能参与 ESRP1 调节的 miRNA。
这些结果表明,ESRP1 是乳腺癌精准治疗的有价值靶点,也是乳腺癌患者预后的潜在生物标志物。